{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/corticosteroids-topical-skin-nose-eyes/","result":{"data":{"firstChapter":{"id":"d7e6a05a-1ad6-5002-9e1d-418bb0509a7e","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field ae28b1e3-5331-4ab0-8977-0cafee4c05b2 --><h1>Corticosteroids - topical (skin), nose, and eyes: Summary</h1><!-- end field ae28b1e3-5331-4ab0-8977-0cafee4c05b2 -->","htmlStringContent":"<!-- begin item 36b3035d-87cd-450b-8733-54f230e70eb0 --><!-- begin field a19ac590-2f67-411e-800b-fa1fde816499 --><ul><li>Corticosteroids are synthetic analogues of the natural hormones that are produced by the adrenal cortex.</li><li>Local corticosteroids are predominantly glucocorticoids. They have four main effects:<ul><li>Anti-inflammatory.</li><li>Immunosuppressive.</li><li>Anti-proliferative (anti-mitotic).</li><li>Vasoconstrictive.</li></ul></li><li>Topical corticosteroids exert these effects on the skin:<ul><li>Eczema — the anti-inflammatory and immunosuppressive effects are important.</li><li>Psoriasis — is characterized by rapid cell turnover, and the anti-mitotic effects are important.</li></ul></li><li>Intranasal corticosteroids exert these effects on the nasal mucosa.<ul><li>They relieve or prevent the symptoms associated with allergic rhinitis.</li><li>They can also be used in the short term to shrink nasal polyps.</li></ul></li><li>Corticosteroid eye preparations control inflammation of the eye due to allergy, trauma, or infection.</li><li>The length of treatment with topical corticosteroids depends on the diagnosis.<ul><li>Generally, very potent corticosteroids should not be used at any site for more than 4 weeks continuously, and potent corticosteroids should not be used continuously at any site for longer than 8 weeks. If treatment is indicated for longer, intermittent dosing and gradual tapering of the dose should be considered, and more frequent monitoring for adverse effects should be arranged.</li></ul></li><li>Adults using intermittent or short term courses of potent or very potent topical corticosteroids, and children using topical corticosteroids of any potency should be offered an annual review to assess for steroid atrophy and other adverse effects.</li><li>Topical corticosteroids should be avoided in people with bacterial, fungal, or viral skin lesions; rosacea; perioral dermatitis; acne vulgaris; or anogenital pruritus, and they should not be used indiscriminately for the treatment of itch.</li><li>Local adverse effects of topical corticosteroids occur mostly on the face, in skin folds, and in areas that are treated long term. Adverse effects include:<ul><li>Transient burning or stinging.</li><li>Skin atrophy.</li><li>Permanent striae.</li><li>Acne vulgaris (or worsening of existing acne) or rosacea.</li></ul></li><li>Intranasal corticosteroids:<ul><li>Are more likely to cause systemic adverse effects when delivered by intranasal drops compared with sprays.</li><li>Should not be used in the presence of untreated nasal infections; after nasal surgery before healing has occurred, unless on specialist advice; or if there is pulmonary tuberculosis.</li></ul></li><li>Local adverse effects from intranasal corticosteroids include dryness, irritation, and nosebleeds. If adverse effects are severe, this may require stopping treatment temporarily. Skin erythema and rash, itching, headache, and disturbance of smell and taste may also occur.</li><li>Corticosteroid eye preparations:<ul><li>Should always be initiated in secondary care. Treatment may be continued and monitored in primary care following a specialist management plan.</li><li>May cause increased intraocular pressure, leading to corticosteroid-induced glaucoma.</li><li>May cause corticosteroid-induced cataract if use is prolonged.</li><li>Should not be used with soft contact lenses — lenses should be removed before instillation of drops, and not worn during the period of treatment.</li></ul></li></ul><!-- end field a19ac590-2f67-411e-800b-fa1fde816499 --><!-- end item 36b3035d-87cd-450b-8733-54f230e70eb0 -->","topic":{"id":"091d926b-472d-55aa-b732-215f8299eb6e","topicId":"fe2967bf-dc0e-4dd2-903c-812a35c0d510","topicName":"Corticosteroids - topical (skin), nose, and eyes","slug":"corticosteroids-topical-skin-nose-eyes","aliases":[],"chapters":[{"id":"d7e6a05a-1ad6-5002-9e1d-418bb0509a7e","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"30c29984-be54-5cc7-b45b-ccea8330c500","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"01ed2c05-1414-51dd-85da-6ddc4bbc005d","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"791cb5ff-e017-51d6-b7ee-cabacb293b82","slug":"changes","fullItemName":"Changes"},{"id":"110d5d5e-8e14-51d5-ab15-5afa0d551cf7","slug":"update","fullItemName":"Update"}]},{"id":"6481ae53-8731-5bbf-84bb-f9c18452558f","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"746ed409-c3cc-5d5f-a043-6c7e517b0f61","slug":"goals","fullItemName":"Goals"},{"id":"40ab5ace-33b8-5a2c-a6bb-cbd7fe8ca07c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cc1a105d-dd83-5e54-b930-588a3dbdb5cd","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f6a0228b-0765-5b1b-b1b7-25eca749a1ab","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"842d280b-d84c-5903-bbdb-3f4fe26412fc","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"17589721-7493-5da3-8828-e2b4bec649b7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"e1a50e32-af60-5677-ad61-93b4be058bdd","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"e28586d8-7d65-5f08-a10b-d2d25b975112","slug":"definition","fullItemName":"Definition"},{"id":"58a9256e-a859-56a0-a7a3-946a224e6310","slug":"action-of-local-corticosteroids","fullItemName":"Action of local corticosteroids"},{"id":"8e053a89-aa32-5f75-aefc-61b421905b9d","slug":"availability","fullItemName":"Availability"}]},{"id":"1967c89c-d7ce-51d0-a539-3bf6738b65b4","slug":"management","fullItemName":"Management","subChapters":[{"id":"b60ad525-96a0-5836-9db8-d24fc5c18423","slug":"topical-treatment","fullItemName":"Scenario: Topical treatment"},{"id":"520275be-3f1d-5e10-8de2-5524f170f2ba","slug":"intranasal-corticosteroid-treatment","fullItemName":"Scenario: Intranasal corticosteroid treatment"},{"id":"f718a357-8e9a-50d8-ad33-87c1b4345715","slug":"eye-treatment","fullItemName":"Scenario: Eye treatment"}]},{"id":"ebd50a03-95ac-50a9-8a2d-4d615c9569bb","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"0620ec75-3526-5198-b134-4f31d225ab30","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"2b03e883-8770-59d5-9965-04ffada0e471","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"73e06218-1739-5de2-908f-ba65ba970168","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f813f700-2fb0-5989-90bd-2c2aa6dbb85a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e3aa0e05-0446-53c0-9de1-2a8d2a9d1a70","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2a6ead30-5d09-5a96-b6d4-b673b755b98a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e78ffc84-8544-5685-8a35-65c8f05aac92","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"091d926b-472d-55aa-b732-215f8299eb6e","topicId":"fe2967bf-dc0e-4dd2-903c-812a35c0d510","topicName":"Corticosteroids - topical (skin), nose, and eyes","slug":"corticosteroids-topical-skin-nose-eyes","aliases":[],"topicSummary":"Corticosteroids are synthetic analogues of the natural hormones that are produced by the adrenal cortex.","lastRevised":"Last revised in September 2020","nextPlannedReviewBy":"2025-06-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2025-05","nextPlannedReviewByDisplay":"May 2025","specialities":[{"id":"45db1917-4d65-58d8-af3d-568321e486ed","name":"Drugs and devices","slug":"drugs-devices"}],"chapters":[{"id":"d7e6a05a-1ad6-5002-9e1d-418bb0509a7e","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"30c29984-be54-5cc7-b45b-ccea8330c500","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"01ed2c05-1414-51dd-85da-6ddc4bbc005d","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"791cb5ff-e017-51d6-b7ee-cabacb293b82","slug":"changes","fullItemName":"Changes"},{"id":"110d5d5e-8e14-51d5-ab15-5afa0d551cf7","slug":"update","fullItemName":"Update"}]},{"id":"6481ae53-8731-5bbf-84bb-f9c18452558f","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"746ed409-c3cc-5d5f-a043-6c7e517b0f61","slug":"goals","fullItemName":"Goals"},{"id":"40ab5ace-33b8-5a2c-a6bb-cbd7fe8ca07c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cc1a105d-dd83-5e54-b930-588a3dbdb5cd","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f6a0228b-0765-5b1b-b1b7-25eca749a1ab","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"842d280b-d84c-5903-bbdb-3f4fe26412fc","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"17589721-7493-5da3-8828-e2b4bec649b7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"e1a50e32-af60-5677-ad61-93b4be058bdd","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"e28586d8-7d65-5f08-a10b-d2d25b975112","slug":"definition","fullItemName":"Definition"},{"id":"58a9256e-a859-56a0-a7a3-946a224e6310","slug":"action-of-local-corticosteroids","fullItemName":"Action of local corticosteroids"},{"id":"8e053a89-aa32-5f75-aefc-61b421905b9d","slug":"availability","fullItemName":"Availability"}]},{"id":"1967c89c-d7ce-51d0-a539-3bf6738b65b4","slug":"management","fullItemName":"Management","subChapters":[{"id":"b60ad525-96a0-5836-9db8-d24fc5c18423","slug":"topical-treatment","fullItemName":"Scenario: Topical treatment"},{"id":"520275be-3f1d-5e10-8de2-5524f170f2ba","slug":"intranasal-corticosteroid-treatment","fullItemName":"Scenario: Intranasal corticosteroid treatment"},{"id":"f718a357-8e9a-50d8-ad33-87c1b4345715","slug":"eye-treatment","fullItemName":"Scenario: Eye treatment"}]},{"id":"ebd50a03-95ac-50a9-8a2d-4d615c9569bb","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"0620ec75-3526-5198-b134-4f31d225ab30","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"2b03e883-8770-59d5-9965-04ffada0e471","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"73e06218-1739-5de2-908f-ba65ba970168","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f813f700-2fb0-5989-90bd-2c2aa6dbb85a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e3aa0e05-0446-53c0-9de1-2a8d2a9d1a70","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2a6ead30-5d09-5a96-b6d4-b673b755b98a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e78ffc84-8544-5685-8a35-65c8f05aac92","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"091d926b-472d-55aa-b732-215f8299eb6e"}},"staticQueryHashes":["3666801979"]}